Get started
Author

Gisbert Selke

Observed names: G Selke, G. Selke, G. W. Selke, Gisbert W Selke, Gisbert W. Selke, Gisbert W.Selke, Selke, Gisbert, Selke, Gisbert W.
ORCID: 0000-0002-9614-9875
Observed ORCID: 0000-0002-9614-9875
OpenAlex ID: A5000053019
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study
2009 · L. G. Hemkens, U. Grouven, et al. · Diabetologia · 614
PDF
Policies for biosimilar uptake in Europe: An overview
2017 · Evelien Moorkens, Arnold G. Vulto, et al. · PLoS ONE · 381
PDF
Introduction to drug utilization research
2024 · Björn Wettermark, Monique Elseviers, et al. · Wiley eBooks · 212
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
2018 · Brian Godman, Anna Bucsics, et al. · Frontiers in Public Health · 167
PDF
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
2014 · Brian Godman, Rickard E Malmström, et al. · Expert Review of Clinical Pharmacology · 124
Personalizing health care: feasibility and future implications
2013 · Brian Godman, Alexander E Finlayson, et al. · BMC Medicine · 107
PDF
Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
2013 · Rickard E. Malmström, Brian B. Godman, et al. · Frontiers in Pharmacology · 91
PDF
The German experience in reference pricing
1998 · Giovanni Giuliani, Gisbert Selke, et al. · Health Policy · 84
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
2021 · Brian Godman, Andrew Hill, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 83
PDF
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
2021 · Evelien Moorkens, Brian Godman, et al. · Frontiers in Pharmacology · 76
PDF
Integrative Review of Managed Entry Agreements: Chances and Limitations
2020 · Carolina Zampirolli Dias, Brian Godman, et al. · PharmacoEconomics · 64
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
2016 · Michael Ermisch, Anna Bucsics, et al. · Frontiers in Pharmacology · 57
PDF
Improving the managed entry of new medicines: sharing experiences across Europe
2012 · Brian Godman, Ken Paterson, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 52
PDF
Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA
2019 · Patricia Vella Bonanno, Anna Bucsics, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 51
PDF
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
2019 · Brian Godman, Andrew Hill, et al. · Generics and Biosimilars Initiative Journal · 48
PDF
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation
2017 · Patricia Vella Bonanno, Michael Ermisch, et al. · Frontiers in Pharmacology · 46
PDF
What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?
1998 · Sebastian Schneeweiss, Oliver Schöffski, et al. · Health Policy · 46
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs
2014 · Brian Godman, Rickard E. Malmström, et al. · Frontiers in Pharmacology · 45
PDF
Comparison of drug prescribing before and during the COVID ‐19 pandemic: A cross‐national European study
2022 · Iva Selke Krulichová, Gisbert W. Selke, et al. · Pharmacoepidemiology and Drug Safety · 44
PDF
Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe
2015 · Wojciech Matusewicz, Brian Godman, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 44
PDF
Non‐antiarrhythmic drugs prolonging the QT interval:considerable use in seven countries
2002 · Fabrizio De Ponti, Elisabetta Poluzzi, et al. · British Journal of Clinical Pharmacology · 44
PDF
Quality Indicators as a Tool in Improving the Introduction of New Medicines
2014 · Stephen M. Campbell, Brian Godman, et al. · Basic & Clinical Pharmacology & Toxicology · 42
PDF
Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs
2009 · Brian Godman, Ulrich Schwabe, et al. · PharmacoEconomics · 41
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
2019 · Caridad Pontes, Corinne Zara, et al. · Applied Health Economics and Health Policy · 40
PDF
Patterns and prevalence of antidepressant drug use in the German state of Baden‐Wuerttemberg: a prescription‐based analysis
2007 · M. Ufer, S. A. Meyer, et al. · Pharmacoepidemiology and Drug Safety · 40
Works count: 90
Citation count: 2,834
H-index: 26
I10-index: 31
Year
Topic
Type